0000950170-21-003079.txt : 20211104 0000950170-21-003079.hdr.sgml : 20211104 20211104161946 ACCESSION NUMBER: 0000950170-21-003079 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Longboard Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001832168 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40192 FILM NUMBER: 211380287 BUSINESS ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 950 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 619-592-9775 MAIL ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 950 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 lbph-20211104.htm 8-K 8-K
0001832168false00018321682021-11-042021-11-04

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2021

 

Longboard Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

1-40192

84-5009619

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

4275 Executive Square, Suite 950

La Jolla, CA

 

92037

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (619) 592-9775

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

LBPH

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 4, 2021, Longboard Pharmaceuticals, Inc. ("Longboard") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing, unless Longboard expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

 

Description

99.1

 

Press release dated November 4, 2021

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Longboard Pharmaceuticals, Inc.

 

 

 

 

Date: November 4, 2021

 

By:

/s/ Kevin R. Lind

 

 

 

Kevin R. Lind

 

 

 

President and Chief Executive Officer

 

 EX-99.1 2 lbph-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

 

img58896055_0.jpg 

 

Longboard Pharmaceuticals Provides Corporate Update and

Reports Third Quarter 2021 Financial Results

Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies
Initiating a Phase 1b/2a clinical trial evaluating LP352 in approximately 50 participants with developmental and epileptic encephalopathies (DEEs) in Q1 2022
IND-enabling preclinical studies for LP143 and LP659 ongoing
Continuing to strengthen key expertise and leadership

 

SAN DIEGO, Calif., November 4, 2021 – Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

 

"This quarter we successfully completed the MAD portion of our Phase 1 clinical trial for our lead asset, LP352, and we look forward to initiating our first clinical trial in patients with severe and refractory epilepsies next quarter. We are collaborating with a world-class CRO and have commenced key activities for trial readiness and site activation. We continue to engage with thought leaders, advocacy groups and caregivers in order to prioritize enrollment optimization, and most importantly, the best outcome for patients living with these devastating diseases," stated Kevin R. Lind, Longboard’s President and Chief Executive Officer. "For LP143 and LP659 we look forward to sharing additional preclinical data that support the scientific rationale for our initial areas of focus as we approach IND submissions for each program in 2022."

 

Program Overview:

LP352, an oral, highly selective, centrally acting 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist, has successfully completed the SAD/MAD portions of a Phase 1 clinical trial, informing the optimal expected dose range for the next phase of development. We plan to initiate a Phase 1b/2a clinical trial in participants with DEEs, such as Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, CDKL5 deficiency disorder, among others, in the first quarter of 2022.
LP143, an oral, centrally acting full agonist to the cannabinoid type 2 (CB2) receptor targeting a broad range of neurodegenerative diseases, with an initial focus in amyotrophic lateral sclerosis (ALS), is currently in Investigational New Drug (IND)-enabling studies and we anticipate submitting an IND application to the United States Food and Drug Administration (FDA) in the first quarter of 2022.

 

 

LP659, an oral, selective, centrally acting sphingosine-1-phosphate (S1P) receptor modulator targeting a range of central nervous system neuroinflammatory diseases, is currently in IND-enabling studies and we anticipate submitting an IND application to the FDA in the second half of 2022.

 

Leadership Update:

 

In October 2021, Steven W. Spector, J.D., joined the Company as general counsel. Most recently, Mr. Spector served as part-time general counsel for several public companies, including Longboard, Dynavax Technologies and Galecto, Inc. Prior to this, he served as general counsel of Arena Pharmaceuticals, Inc. for nearly twenty years, from October 2001 to March 2020.

 

Third Quarter 2021 Financial Results:

 

Balance Sheet Highlights

 

At September 30, 2021, Longboard’s cash, cash equivalents and short-term investments were approximately $112.6 million and approximately 16.9 million shares of Longboard voting and non-voting common stock were outstanding.

 

Operating Results

 

Research and development (R&D) expenses were $4.1 million for the three months ended September 30, 2021 compared to $1.6 million for the three months ended September 30, 2020. R&D expenses for the three months ended September 30, 2021 included $1.3 million in preclinical and clinical trial expenses related to LP352, $1.3 million in preclinical expenses related to advancing LP143 and LP659 and $1.3 million in personnel-related expenses. R&D expenses for the three months ended September 30, 2020 included $0.3 million in preclinical and clinical trial expenses related to LP352, $0.8 million related to preclinical expenses for LP143 and LP659 and $0.5 million in personnel-related expenses.

 

General and administrative (G&A) expenses were $2.3 million for the three months ended September 30, 2021 compared to $0.9 million for the three months ended September 30, 2020. G&A expenses for the three months ended September 30, 2021 included $1.0 million of personnel-related costs, $0.5 million of professional services and consulting expenses and $0.5 million of insurance expense. G&A expenses for the three months ended September 30, 2020 included $0.6 million of personnel-related costs and $0.3 million in professional services and consulting expenses.

 

Net loss was $6.3 million, or $0.38 per share, for the three months ended September 30, 2021 compared to $2.6 million, or $0.66 per share, for the three months ended September 30, 2020.

 

 

 

 

About Longboard Pharmaceuticals

 

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2c receptor superagonist, with negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes, in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

 

Forward-Looking Statements

 

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “expected”, “potential”, “plan”, “anticipate”, “focused on”, “look forward” and “build out”, and include, without limitation, statements about the following: Longboard’s clinical and preclinical product candidates and programs, including clinical trial protocols (for example, clinical trial participants, indications and treatments), timing of initiation of clinical trials, data supporting the scientific rationale for our focus, regulatory applications and their submission timing, progress, and other plans; our team; and our focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: Risks related to Longboard’s limited operating history, financial position and need for additional capital; Longboard will need additional managerial and financial resources to advance all of its programs, and you and others may not agree with the manner Longboard allocates its resources; risks related to the development and commercialization of Longboard’s product candidates; Longboard’s product candidates are in the early phase of a lengthy research and development process, the timing, manner and outcome of research, development and regulatory review is uncertain, and Longboard’s product candidates may not advance in research or development or be approved for marketing; enrolling participants in Longboard’s ongoing and intended clinical trials is competitive and challenging; the duration and severity of the coronavirus disease (COVID-19) outbreak, including but not limited to the impact on Longboard’s clinical trials and operations, the operations of Longboard’s suppliers, partners, collaborators, and licensees, and capital markets, which in each case remains uncertain; risks related to unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Longboard or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; topline data may not accurately reflect the complete results of a particular study or trial; risks related to relying on licenses or collaborative arrangements; other risks related to Longboard’s dependence on third parties; competition; product liability or other litigation or disagreements with

 

 

others; government and third-party payor actions, including relating to reimbursement and pricing; risks related to regulatory compliance; and risks relate to Longboard’s and third parties’ intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

 

Corporate Contact:

Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com 

IR@longboardpharma.com

619.592.9775

 

###

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial Tables Follow

 

 

 

LONGBOARD PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

(Unaudited)

 

 

 

September 30,

 

 

December 31,

 

(in thousands, except share and per share data)

 

2021

 

 

2020

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

75,461

 

 

$

55,316

 

Short-term investments

 

 

37,098

 

 

 

—

 

Prepaid expenses and other current assets

 

 

2,740

 

 

 

46

 

Total current assets

 

 

115,299

 

 

 

55,362

 

Right-of-use assets

 

 

600

 

 

 

—

 

Property and equipment

 

 

16

 

 

 

—

 

Other long-term assets

 

 

33

 

 

 

—

 

Deferred financing costs

 

 

—

 

 

 

876

 

Total assets

 

$

115,948

 

 

$

56,238

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

891

 

 

$

1,213

 

Accrued research and development expenses

 

 

1,653

 

 

 

916

 

Accrued other expenses

 

 

231

 

 

 

845

 

Accrued compensation and related expenses

 

 

918

 

 

 

161

 

Right-of-use liabilities, current portion

 

 

328

 

 

 

—

 

Total current liabilities

 

 

4,021

 

 

 

3,135

 

Right-of-use liabilities, net of current portion

 

 

275

 

 

 

—

 

Commitments and contingencies (see Note 9)

 

 

 

 

 

 

Convertible preferred stock:

 

 

 

 

 

 

Series A convertible preferred stock $0.0001 par value; authorized shares - none and 5,600,000 at September 30, 2021 and December 31, 2020, respectively; issued and outstanding shares - none and 5,600,000 at September 30, 2021 and December 31, 2020, respectively; aggregate liquidation preference – none and $56,000 at September 30, 2021 and December 31, 2020, respectively

 

 

—

 

 

 

55,795

 

Stockholders' equity (deficit):

 

 

—

 

 

 

 

Preferred stock, $0.0001 par value; authorized shares - 10,000,000 and none at September 30, 2021 and December 31, 2020, respectively; issued and outstanding shares - none at September 30, 2021 and December 31, 2020

 

 

—

 

 

 

—

 

Voting common stock, $0.0001 par value; authorized shares - 300,000,000 and 10,500,000 at September 30, 2021 and December 31, 2020, respectively; issued and outstanding shares - 13,237,500 and 3,840,540 at September 30, 2021 and December 31, 2020, respectively, both excluding 348,450 shares subject to repurchase

 

 

1

 

 

 

—

 

Non-voting common stock, $0.0001 par value; authorized shares - 10,000,000 and none at September 30, 2021 and December 31, 2020, respectively; issued and outstanding shares - 3,629,400 and none at September 30, 2021 and December 31, 2020, respectively

 

 

—

 

 

 

—

 

Additional paid-in capital

 

 

145,099

 

 

 

11,708

 

Accumulated other comprehensive loss

 

 

(24

)

 

 

—

 

Accumulated deficit

 

 

(33,424

)

 

 

(14,400

)

Total stockholders' equity (deficit)

 

 

111,652

 

 

 

(2,692

)

Total liabilities, convertible preferred stock and stockholders' equity (deficit)

 

$

115,948

 

 

$

56,238

 

 

 

 

 

 

LONGBOARD PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended
September 30,

 

 

Period from
January 3, 2020
 (Inception) through
 September 30,

 

(in thousands, except share and per share data)

2021

 

 

2020

 

 

2021

 

 

2020

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

$

4,093

 

 

$

1,603

 

 

$

13,406

 

 

$

2,462

 

General and administrative

 

2,262

 

 

 

947

 

 

 

5,639

 

 

 

1,829

 

Total operating expenses

 

6,355

 

 

 

2,550

 

 

 

19,045

 

 

 

4,291

 

Loss from operations

 

(6,355

)

 

 

(2,550

)

 

 

(19,045

)

 

 

(4,291

)

Interest income, net

 

23

 

 

 

—

 

 

 

40

 

 

 

—

 

Other expense

 

(13

)

 

 

—

 

 

 

(19

)

 

 

—

 

Net loss

$

(6,345

)

 

$

(2,550

)

 

$

(19,024

)

 

$

(4,291

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

$

(0.38

)

 

$

(0.66

)

 

$

(1.41

)

 

$

(1.13

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding, basic and diluted

 

16,866,900

 

 

 

3,840,540

 

 

 

13,538,458

 

 

 

3,798,025

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(6,345

)

 

$

(2,550

)

 

$

(19,024

)

 

$

(4,291

)

  Unrealized loss on short-term investments, net

 

10

 

 

 

—

 

 

 

(24

)

 

 

—

 

Comprehensive loss

$

(6,335

)

 

$

(2,550

)

 

$

(19,048

)

 

$

(4,291

)

 

 

 

 

 

 

 GRAPHIC 3 img58896055_0.jpg GRAPHIC begin 644 img58896055_0.jpg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end EX-101.LAB 4 lbph-20211104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information, Former Legal or Registered Name Entity Information, Former Legal or Registered Name Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Soliciting Material Written Communications Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Trading Symbol Trading Symbol Title of 12(b) Security Title of 12(b) Security Security Exchange Name Security Exchange Name Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, Address Line Two Health Care Organizations [Abstract] Document Information [Table] Entity Addresses, Address Type [Axis] Address Type [Domain] Former Address [Member] Document Information [Line Items] Former Address [Member] EX-101.SCH 5 lbph-20211104.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 lbph-20211104_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.PRE 7 lbph-20211104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 lbph-20211104_htm.xml IDEA: XBRL DOCUMENT 0001832168 2021-11-04 2021-11-04 0001832168 false 8-K 2021-11-04 Longboard Pharmaceuticals, Inc. DE 1-40192 84-5009619 4275 Executive Square Suite 950 La Jolla CA 92037 619 592-9775 false false false false Common stock, par value $0.0001 per share LBPH NASDAQ true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 04, 2021
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 04, 2021
Entity Registrant Name Longboard Pharmaceuticals, Inc.
Entity Central Index Key 0001832168
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 1-40192
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-5009619
Entity Address, Address Line One 4275 Executive Square
Entity Address, Address Line Two Suite 950
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 619
Local Phone Number 592-9775
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Trading Symbol LBPH
Title of 12(b) Security Common stock, par value $0.0001 per share
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports lbph-20211104.htm lbph-20211104.xsd lbph-20211104_def.xml lbph-20211104_lab.xml lbph-20211104_pre.xml lbph-ex99_1.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lbph-20211104.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "lbph-20211104_def.xml" ] }, "inline": { "local": [ "lbph-20211104.htm" ] }, "labelLink": { "local": [ "lbph-20211104_lab.xml" ] }, "presentationLink": { "local": [ "lbph-20211104_pre.xml" ] }, "schema": { "local": [ "lbph-20211104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lbph", "nsuri": "http://www.longboardpharma.com/20211104", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "lbph-20211104.htm", "contextRef": "C_47dc1493-0f8e-4e6c-abd8-512c8d3a06a1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "lbph-20211104.htm", "contextRef": "C_47dc1493-0f8e-4e6c-abd8-512c8d3a06a1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name", "verboseLabel": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r5", "r6" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]", "terseLabel": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.longboardpharma.com/20211104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r6": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r7": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r9": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0000950170-21-003079-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-21-003079-xbrl.zip M4$L#!!0 ( ':"9%,[D7KI&10 %/> 1 ;&)P:"TR,#(Q,3$P-"YH M=&WM76U3X\:6_KSY%;W.)@6UM*W6NPS#+0),PLT,4)C43>V75*N[A;4C2XXD M@WU__3W=DHP-9FR,8>1!224SLOKUO#Q]3I_3K8-_C <1NA5I%B;QAQ9I:RTD M8I;P,+[YT#KJ'9^=M?YQ>/#?&*.3CV?GZ%SA'&61*,IH/)G=$)S@;JZIA-,"-;,:V)WB=75S+9A._K_:EI7T^YK)<-)&M[T<[3# M=I&L!#W'L8BB"?H8QC1F(8U0K^IR#\;(VN@HBM"5K)6A*Y&)]%;PMFSRAX-^ M#K0 >L39A];,N.^,=I+>=(CG>9VQ+-,J"G7'?AKQ<%I6/JJ2NJ;9G>+E7-%\ M85&K*)K/%@WG!C!;VN@ $7.8FJC* ]F_?*6X?.W3;%I\_*C\W/SDVZIH.'ZJ M72*'(?DMV5T5CY/X'-B>AFQQ-9ZGG7PR%!THB..BY'U7^>)*]]UT\I3&69"D M R4J9A'XM#%OQ]TBK_*'P:=0PXYLM5,V>^ G?*):XN$MRO)))#ZT>)@-(SJ1LBGV M6X<'X;@KBXNT^&O(N8C57^^%%X7\0^OC7X;%C" P&78,2K'I4 M34W>PL+A& M7=>S!0'IC>E ]B+"[FD,4YD@;6 M E=@4]@,4Y^[V"(Z<[E!-9N2UJ$&@N8:.K'=@\[V2QSF"ML17C [TB. 9B[A^6-$;]8;84"C3#P:7&>>I*D(1 J+B<@. M#R2L=#.E.- 14C#3E<+TH96%@V$DM4C]UD_E.*2*X$H%VN., ^LZ\VT4W0R^<@%"E20Q +4>;X[/=Y]CVL?%C] M--_Z$ B8\.H)<"7-Y4IX>+\05O7NWTV'R9\H6KVIGJM..G.DJ>@X)5QG1DENWM&&.>#+R([$_I%Q:#>H5V!'#?%\V#S I)]_5 MVMI/^P%TB;/PWZ)+-%5B0-.;,%95BA\D2..^D,LS-&(4-0(Z"*-)]SH M^'1'VU/_[NX_^HWL[C]-J+MBH'X2\=FYN2M0[H_SL^O3$]2[/KH^[34$?#X! M>Z?'?UR=79^=]M#1^0DZ_?/XMZ/S7T_1\<7GSV>]WMG%>4/5>:KJ*U#U7T>] MW\[.?[V^.-]#)^WC-G@2ENE5E)P=\9L-"3W%QY+0$MNZIF+D(\Y6.%PR@]QW M]P2[O4?L-I<.<1'#RZ7AOE]-K@[@\86\*I\6S=\/_&ORL1:U8VG71S/SM9]! M[@K:7Z(\CZFYMU!:I7E M%*RFJ]/S:W1U>GEQ=5W/E;WAW]-$NQREV8C&.I9 MT#0"+N=(W,HH0ZI>"[[;76:)K-+IXCTV,[ =S7>PY5LN6!6NAEV=^=@S7-\B MCF43S=N4)7*I]FE.B]V;%BIVJC^TPG'>Y?#+ #KIW8N"+ M%)E[*C"SQ'YI+(C&@EA(G/LAZ,NY]83N$D-8 3-MS#501I-K'/N&;F+'";C0 MA!\X1'NI[A:[_U?B)LQD>"D_AS=OKYHKT>A3%6U"ERKQJ^ZHXCN@D&>7= M(!P+OG\7\KP/Y%/T+"O K"(ZS$0W$T.:@GTW+S:J;1D]EP-(J]YOPRSTPPB6 MG&Y5ORP$I?@TVJ6Z,XRV81@_26IVCF([#$P,T\GQPF? M]U=D-HZ,6.=BF":WLIW:.BPG(J)WX% M=U06*D@CTZ\ATT)H'F&&A<'?-K&I M&0ZF!CCA'G&-0##=:TWED\#TB:PS[KF=CSW<=UPC\@&ET,V[S$>>IR++RCT] '5)3E]G4'0N=C@4;R;.U MJ/?W:/E>9!WGL?>*&3@@+GH@MP&%ATV'6=C7"<4.MPSA^ ZU;>>UI$:OJ=3T M1M H\BQMA7V6=P LOJ\S0[-,;' >8#-@/G8U/< 6%X;EV([--Y7H4)Z<""H_M4BHGC8\\R*2:N,&S+\ T>;"BJ M4(J)V@Z[2"_3Y#:4!\;K2?#CH[<^9+#*J-"K&,V5.:;"]UJ;:-(:6VRYK6J3 MF\#?+BGA.%M9]5L1V[5=M=:S)<0ACCFEAP"<'FY9A@/ECFU@/M, D M8!J9=+.@=9ED.8W^+QRJJ'X](U%%.9VWB9PK(:#FDTXT%= M!$'(1/8ZN^O-\O$.EX_WKG"P%""Y%GQUGQ[^E&F/]3]84)!'<^)Q;,*HL.=8 M+O:%I@E!/8<'+]Z@DZZSG$N-K8OE^2MU'/7NJ_G-C-BF<#0#6QH!$]3Q#>Q1 MR\=""[AAZX:P+?92L?B4 (I?2MFO=8:3Y>F@$HY5=X^Y@>%5SRMVCC9"MG=F M$WP$0U"DZ%P=,DI1^5B:YGLH#.3!HOA&<-23.U_H$\WR\C1O<]3HN5+1'#5Z M%6!:Y!6]AGX]HMQJN[)]P;ZHVPWH<)@FPS24J95^,D:^B)([J6+RI=0\Y.+? M41!&TDP,,Q3*^S(YJ%Z>H"P3BE+; CE#EM67=C"KT>I6IZ2'2-3(=5CJ@MO(5P M[H3:Y@ZDO>CXF2F;_NJQ,L]^4.3-[.,4^P,/]A) *%Z83?.-A&P3)C\A M 7,\!J0+/!N;@6=BC_@V=D2@VV#7,RUXL]*-$&_'0ER**0C[K)RBX+].Q M[]H&-CTP_87)B&N:+T7?'K@/# 0TOOD,2SU8EU$#O8T$UXNS]S**!J60/L9= M(C-X]!GHG;L";@J\X!L7)1OL_6XE=Q/8:P>:T)A+L,$]%YO(LR"IF,\*ZU XF)L?Z MCK^[&B(791M,_FXE>1.8S$VF>[Y%,'48V,-07\U9!YK)LK9&YADE']1:9F5VI(LHC4L'G!&5Z MR[9:PLNH#PA'MPFRU#'(8KA+HRQD>0EK XV8#QOYMCG7\S%SK6W-Q,R;1-"U MNY1<;BUO861^QB&;9&QYL_PI#D6I5MZR]ZC]I2^QN'9^W\;Z!1L\VKV9V\6OM%Y36"HP"=P2_WWD2= M[F"1FPPUSW/8Q/:8:U+/MVR*G8"ZV"3"P;X(X)$180C'M2WRXF,;I>=^+2Y\WKKSS*_R%>6& MRJ\ "9YC,(\S%ZK)JY:HHV&J,P\;-" "GH1P7WPC2FFG%G97;?'@TR^7OS6J MWJAZ+:F\D>!80!R/!CH./"(3%HB)728H:#%S-,L.B$[T3:W^5;A ?>7J44!, MFH5O]JV']=#@NB_0.E\ 0="J,O"'QP]"3,$DQ# AQN9_P53N,O[,L0UE,=1:(:X"(!RZD-6 M1?ZM9BWX'NC]9T -M",!R=E7YZTU;U_EXE:5H#L0[:'\%)8\T%;$RW0?ZRM^ M8_11XS*&=E]_IOGV1B(I[TQV3I^0@Z\?>5XEU+/XTAW?,GQ3\W'@4P^;%K.Q M1RP#6\+13)N3P-9?G'!07+I33>Q7-:_C8EHUS#58+6KF.::]0JI!(_:K0F;P M%1#< ^A;B*CAHW-\?196VZ]VF8%MF2XAIHTMS[&P22P?>QKWL' Y,W0O\'S^8G.I5.WQ M]92DQ:=]:ZC7F\TAJE%FP!NZ-7+6_>G&YI#>B,)AP32 (71I=$D7A*1!=2PVY[MK$=U*@/'E[( M[U;,?^=\#RWYO+)T$ QS?UI*/>V"FY.-8'&DL$[*2^U26*4IK,PTCF&B3)WH M!^F_7V/34A_DVERL0<52WA/@::C1&5HQO#8Z@C5M.#W'/]^; M]+7RG(()P1&X8@)6:"K=G'[HASGRO#992;/LMFT[SY4EK^TMH??F4\#6A_G- MS9N S-NS_[C; .;K[[J$<6'[2+-/6E=4.>]5)BI(X!3SI5U;W7HV*X,/971/ MQG&B2!FTOD!<@)W,47&;&ML/PDCPXH'O*W4! W289$*M)5,#U%W1O]^3&@$& MGM2O/6G^)G+3X@XL8)2-_/^'YJ1=*QN*0EID[Q4MTQQE16=[,-*T'',X.^1P M^IDO> !3/A4!3%!>FQ/&RN(NK^IX\G1QN<'Q:(P+*RR?'3@. %!1>C(6TA$ 6#@3T#-F5HE MN>0/L^("P@&T!7J!W&3@2Z1/LAGF_#0Q)<-$N)J1L-P>T]^=/0;F!IFQNM3E MYC+OO##'2DW-WCMYUT/(';[[7Q4%Z^E/K;/,+K^X=I54Z^WYXKK3!JMX29XT MT(1XRR[&T=JNY[Y.-O5L1AK(?!KJAL7E._G<27W,:;E=4 N4W\J[U[[!\=XZ@/;6\(JB?BH#DY$_[&,Q M]KR_2+N?#UZDC24-5V6S&A47K-P*ZJJ=)CG5YPK Y=Q&-%>[-@_WUJ>:3!L\ M?Y]X3C2S@?,&SK]_7M5'Y8X!A%-T*;?WSR0X4*8^KW5"*M3Z,?/;K^='U M'U>GO28,LD4*X=^C,"VC/*L&2A?D'O)1-$&,CF2^H KVINI3(&58 M+P/"P L9Z8-N?-&G42!#=[(A95B6!50 ;Q1#)=4>'>7])(6Y\%C.QVIKA+"ECK%#&M!]U5C\?8FNO;&_LS(97:_ *AB+??VCIK89O MVV,J+$EWW([]]T'(>22V4Q1JI,*-VC:\:GC5\.J=\JI^Z]HV\[0^)LX)^+M= M]'0XJE'7K537QI7?(AW\9=*MA;Y]JXRN[VI'?QT1* K+,77#' ;,8*"=K(-^ M%[?RYH\V^@24VPYOLX'N[8'NAE?;PZMWMXNS3F2T%IQJ\J->1PV;Q;#^2KO% M -OPJN%5;7G5+(;-8O@HI3R4Q%'GTH_[H0C0Z5BPD4I@O B"D"T^ ]CD)#XO M)_&@XR=\?#Z+#_P!02P,$% @ =H)D4ZHX5-A- P @PL !$ M !L8G!H+3(P,C$Q,3 T+GAS9,U6WV_:,!!^WU_AY6G3YCBA[:1&A:D;JX3$ MN@DVJ6^520ZPYMB9[13X[V_G%R]7^<A-%211U8++8*+98&O0J M?8T!Q'YP&BQB@V*PW<2)4/84Y+ M;OI!*7Z6E+,Y@\R6F8.KSY9!1VW[(G22&87-I@"]%7L]4SR4:D&LFCBUBQSA M*,:]V"-!E'FO1;4(9TA@;4!H-N. G1FHJNX:]US[:[BMPE;(U5D#CV)R]WE< M-]D;:KR@M&@1>B(0T7 M\H%8167>\K;*S.S*.[H@M;)KR@[0MI-J[/2TM/FL6)XP DV09[5I*AE?7EZ2 M2AL,7B!4C1W+"ZD,JJ=O+-.J+0<8NG_8T\1.A..>K5IHG05([)S;/3F2OR/A M6_Q')-KY^%,2OK,N^L6^N#M'X:B(>M_0N0-VAX,QGXWJ:4%W;@=W5T_U7Q_5]UT7UR,/*H0T57 G\L*B8&(N:XF5N:E)_.A,8(ZJ M94JH2I7D<'CE2*%D TYGH=UG;_(LP/8\.S6Q M$.#C1WH>:YAQX+%3:U3MO]?8>O0#;9O FU7XYWD6"D[-TT*T?8Q5W=J?[M>. MU?^6= ;S4Y.V$";8X92'KNCHIPTQ="V%S#Q;WN=%[_V2$6&:F^H MX^Z*/'7RQ'VI(?LB!M7YZ9PUX,;D #"E/"WYZ;CM'N^$-4+?MN:R(D]NJT;0 MN=-J27W-#GX!4$L#!!0 ( ':"9%.YUCP/R04 $0X 5 ;&)P:"TR M,#(Q,3$P-%]D968N>&ULU5O?<^(V$'Z_OT)U7Z[3&F.27!OFR TE28=I?@UP MTYN^W A[ [DXZ=%1-$S"$DX M:SE^K>X@8 $/"1NWG,]]M]WO=+O.IZMW'W]R771]VWU #S!'[4"19[@F,J!< MS@2@]_W[7]"7/WMWZ(ZP;T,L 5WS8!8!4\A%$Z6F3<^;S^>U<$28Y'2F](2R M%O#(0ZZ[-M\1@,WOZ!HK0,U&O>&[ON_6SP?^AZ9_T:R?UR[KC<:O]7JS7M\: MQJ=+0<83A=X'OR S2L_-&%"Z1+>$81803%$_F?0WU&5!#;4I13TS2J(>2!#/ M$-96-JE6T*2)C(4D31E,(,)W/(CIM9PM/8NAH#4NQEZC7C_S-J,*$>8O-X&Y MYB?7;[AG?FTA0P?IU6 RGON(21*XN1NJS8!M\(6WNKF!9DS/SV*L?WEYZ<5W M-U!)\H#:J.]]N;_KQRYQ]6(J[6!PKMXAM/(<%H'@%'HP0NO+S[UNEAUAR@M) MY*TQ'J943QU;F @8%>I/)!G?71BO_;PU4BVGT'(DB:84'.^[.>EK8.9HN"&, M\(RJ-S(LM',ZOCS"A'T_W929LMG&QMT(HB&(MU+-LU$RSXDV)X+9$-R-8][( M=H^E(LX)X5VV9C+*V7C(L0BG$RPB'$=3$_Y\OW[N*;S@C$=++];0TQ]?DXB< M?+=9>,,44%TXB8F8PFO-E0D3)\$PHA!FB=&"@P+!2R$,#%A M%)Q>N*&6D*,\2#&B)O3SG$TJDXTC(:B-^;,7 HFIF(O8YRUAZGYEOGD"0;B.MZ')ZO#3%K)AD/KHJJHN! M7CP9IQNK?5;,,PNMB.0MH? P*PAO&4A%I/2[,A=3+N+G>E_IH]GA,[W=EAT> M%I^7_:,JHC[ BVZHCP89D=6+^P'G%N&KS6/67R;7\P^E,"GL#Z/9> 7-1L4T M._KR40SX/"^G*4)62S$^'H_B2?!G8BHI!WCNPJLE^\2EPO1?,MU[_'/!)R=J M5K M !=02]T^.1E3+*1/$\Z*0WH&4EE(W[RHK9+F.QAC^BA620X("/?F0D<. M/[F8?P11"IC.)*(96T?LO)>^?-S)Z?4Y)8'.(MCX7A]803#-X98#.CFQ)P'& M%Z"#1_QN8DHMXG$TRMVC>\!5$^U*.0/Q*KK9(2 M>+JC59KR37W15@_D=9Y>U!?65!/!N57- M_Z74M\2X5<&T7+G9./_#Y>Z49,O5V[!/;T'-MUS=9_;ISB\FERO[W%;9F3)U MN;HO;-5=4/\N5_T':]7GE-3+E?Z[K=*W"_7E2O[#5LD'V@#E>N'25B\4=A1* M3F0L3-SV]"A*%F]A&K>G\U&R> MSNL)^2LG2K4WKBOHT)>NW-K_+;_V4K-[" M+"_=3RI9KX5Y7;9E5;)F:Q.Z8SMB)?O#PFROH*E6LG +$[R\=EW)Y1H+L[I] MO<"2U5N8UAUN,);L PNSNYU^9RM"8)7DYO7\/6WAS&,;??'S/ 07&%SO42N#QH\^OZJW^EL-INV-;== M#SMKGP[HM4V\[("F1?!#@@QV':X,'T&_U^WIFJYKW7=3_=>^_DN_^Z[]7N^^ M_[G;[7>[L>U0(Z&ZX7C'W"(%Q\FY'?O VD]0\?/G2" MNWM1SQ8)4EB]\_5F/ GTU.@,^=1JJ'7Y B RAS%##IM:"/#Z!#NH@"*[W8D& M#N1]VVAEM?>1:R H&W ^)S820P\R/"7_RD:!YR,"C%(+A/62V M%_BI8R&[PY8!^Z&Q'\RX+^D?WS^[E,ANY,XQ609S>4U_(#)&"\.Y(P]H87L^ M(LBZ-9:(#Q1POF@]^_%.WI)H5K)SID M(]/78PZUQ.W:R; 7H7/_B%UTNU[.A#LW(U([J2DQF-<4*S^)8ZI'SJ8>3XQ3%^TQA/W M:Z?#W=4DT?M,O=H%/2U_)WCC/U(7 M8F6X^23%TK*H;NG)[GHV2U[>2_*S,BDDC1SV!,5I@$GF'@ M>@WQFBZW7:'_4_R4).I38SNRZ-:PYY%C>\2X>?)R'D2G>N,=(QB256;+W#$OVJM*<&]XLB'*L/6UA&*N0*W)\CU\)2&M=/0KI MO(PN?_\#&0X]&PU"OV\6AFO_&WZ/Y?@[ISXE[4T?BWE,C9G0GL $_=@YT_Q\J.PW3]5BXM*1^%%8S8[@0 M D.(# &T%(5J4*5^';(QUY+<#T# D>IA+(S$EB0=84$2K,ZM+H[-/I<^M6_Z M+(N WT S38U!Y>@3B)^6^VTJP!# 0X$ (UDV[T;84 (TD"><22%Z5?=+G65]H=@*8\!T4BAT3?ID2LO*1B43A$.HFB@+ MBLY*DHX*B3CW;R&8O*4_YG5H9UW^P:D4P#9W N)ONC*S,"#)ND*#F'QX^O,( M@TBB8V+Z!EKY6FC-Z/$YP,Q9YQ?ZZ:&]"GMR,D-7. ,-T %89.R4(%L;9@:^J+6 M94XX4UJEAF)>0S.G*2Q34D-5V.;,>69+?A0=;#G-S_MC350YHY:JJ"4Z33=3 M>*)H0XD:I?<[*E-HHH:DJ'V:<\P4;ZBA*&RJYARSU1!J[2ALM4X;-%M3H/*- M)6[ 3KZK!!EYE91SVK*3G$7Y;)6D"YNUD]3SL\!*%:P&N/6BUG"A5Y_)^32 ?+9A7$@] ME2-I '%1&_DQJ_<4D7]F(SE3XSD)!;7>35Y[>=K!$:80&K"0M%ZSQ<2)7$*@0CY#3VS\N7_ K M=OB_@E[^!U!+ P04 " !V@F13D1 $Q7@% #S. %0 &QB<&@M,C R M,3$Q,#1?<')E+GAM;.U;77/:.!1][Z_0>E_:V37&Y&,;)J3#DJ3#;+X&Z&QG M7W:$+4!36?)()L"_WRMCI3'(D,S&;A-XP08=24='5_+5O>;TTSQBZ)Y(105O M.7ZM[B#" Q%2/FXY7_INN]_I=IU/9^].?W%=='[9O4$W9(;:04+OR3E5 1-J M*@EZW[_^@+[^V;M"5Y1_&V)%T+D(IA'A"7+1)$GBIN?-9K-:.*)<"39-H$-5 M"T3D(=?-FN](@O7OZ!PG!#4;]8;O^KY;/QSXQTW_J%D_K'T\.C[YK5YOUNN/ MJHEX(>EXDJ#WP0>D:T'?G!/&%NB2U%";,=33M13J$47D M/0EKRS89C*#)S##FBC95,"$1OA)!2J_E/!K/?"A93D#5%$;$)KUO:_7 M5_UTG"[,4 *J$>?L'4)+.:1@I$=&2%^_]+JY1IC@XZ' ,HPG6$8XG50]"[Y? M/_02/!=<1 M/U_1Z\/&O,0QS;?/P@BUNEDJ=.Y@GA M(0G323'LF0AR(*9-5,B\>GH4"H:16I$B06TL[KV0T)2_ODFE366%+P_,'Q$% M-J2;D$B9AAD>$M9RML*]JL@.H,4-Y-+BRL@\DF* AVP3L35HZ2275M@.0[ V M151VHP5JSZEM@K=4*)WPHP[/180IMW!JD3B(+%0RI>73N<2 MS CZ6^IP3:(AD192-E3Y$PB&'FICOV1X;)N\7'EEJ_2.2"I@4PZUM[%AB>9Q M%:W/'AE3;3H\N<&1C9T55A&Y#J@B,>O"XVC^%UD4LEO%543O DQ\# [L9REF MR:0CHACS8I)V=%54YP.8/$7U_K^TLV*>Z]"*2%Y21FZF!3O*&J0B4N##"QD+ MF3XZ^^ TD8Z8@KDM.B(L7B^;:U5$?8#GW1"6!AW1Y8%BB[A%^&I=A>RB?3M_ MFY>0P_XPFHUGT&Q43+,#M[=R(&8V;Z8(62W%='G_%5R^IZA[E@074,L5ETY&!S'8W43PXBU]#5+9EOYP%EKZJ5=D MC-FM7#HY1))PHR_TQ.JE#^9O21,XJH,G$4UYMF/;SE5V7.GT^H+1 +P(/KZ& M!2LI9A9N%E#IQ.XDT5H0V#S2([N.=LC;T+Z\?"LDP13L?^$WA@,=_;+9X"JD,E(7\V""^9@4;#=66([< MXTA>6^:)8AF8-N%V+$D131$T)PIG-AB8@A(<$" M6T[=03&<*/2@6@ZX35,%I$2L&]+; PP';!0VT*NE"(5T4ZZP7RB2(G\V47+! M."/(MGA8&1*Q'Z[.TZ* 1B-+".YMRF(-ZJTNG76+>IMB% 9>C2#6F.-^2]FR M'V<"^6_+6)[S#%H)")4S=0[W MZA1G!3*-CO8:%:0C,H&.]P*MI$(R8?[8"[,]'9-I]7&OU:;\3Z;2R5ZEHK23 M<15WY'3Q;(D:WR7:X?-%8:;-:+-WIC?E^8Q*>Z^Z.,%H--IUWSJ?VS2J[+HW MO9YD-CG9'J-:B_J8]\3.12O3;>"I+(1Z$4=Z]?UL+?ELXTL+^I)ORY9 M-F7334CQC>4K_H<\EAR^$6F'_>B5=P:,(KON/:^_NV"4V76/V?X"A5&G5%_Y MU%L3!VA^.WN7%>@/_:>YL_\ 4$L#!!0 ( ':"9%.K[Z#YXR< !XU! / M ;&)P:"UE>#DY7S$N:'1M[7UK5^-(MN7W^RMB967UP%JRT^_$D%5K**"R MN$U"-E"W9S[-"DMA.RIEA4L/@_O7SXF0; LP+QO;(;.K5U+L?4X\ MCK[TXX'_ZW^Q+WW!/?HO^Q++V!>_GOR?4KM=KG[YE/Y*%WS*KOC24=[87#ED M43SVQ2\?8G$;EV3@B2#>KY0K/Q]T51"7(OD?L5^EWX?QP8"'/1F48C7<3__@ MRT"4^D+V^O%^M5Q/O]'E ^F/]Z_E0$3L7-RP2S7@P>3+'17':I!]WSR2^[(7 M[/NB&Q]\^/6+OL6D13=]&8M2-.2NV!^&HG03\N'#5CWUT ^__N.G:JMR\.63 MONK7+Y^&-O4YU#>YW^D.=W_T0I4$7LE5O@KWPUZ'[U0<\[_=@P=_J^X>/([3 M3=K.CO*]UP)WBT/WE _W0W-MKMRK-YO^KE/\: M]CXP[L=S_S[!2'IQ?[_6VAO>'F2M:GRFGV<]MZK++CU6A*\U='UI0V?-TLRT M7R_7Z_6?#VP$8AV$T7@!F&G3YD0J' M*N2Q8'\./?T?'G@3]/-=6EN;&6S_)CA>"K)K'+'KOB3[_ROA(366U2JU*OM= M!CQP)??9I8@2/X[N0>[)T3S0&^6F!MV3T=#GX_VN+V[S^+;FXOM7$L6R.R8L M""PRD_Y6*8JI-0<&Q1)U?1#M=W@D]%?G8CZ@/Z0$62G7&Y7:Y]D_>S)X+F19 MA4$"1=[D/\UM5^,!V6T*EPP,-!U?N3]>],4GD'L&$,VBM]U*Y_.41W,6O=L> M6\"Z/W[3BW6;]F5,MG6IH5>)ZXHHZB:^/V:N&@Q]$0N/#6@$2_J9\8@\TI-! MCWDJ$FSGV^'Q+M-.(%7 5)=QS8+T096YU'7-@RP.M1=T5;-8>N&2J- MMC0?"AX/Z!=S023D?Y*0&LFC2)'SZ$??R+A/7^F$BGLLY$%/Z.=$8B1"P<10 M^F(823%S+S)#]F^X&=S,4C<[#20-_UC[T=1C.I]J_+[7B!'WD_0ZXSQ,!HP/ MAZ&ZE0/R#O+19H4-"4?IRB$/2(J,NWCD';X::K^BFU"TD3D*7<9$X(IAG]/' M/.Z3X["=XY.3:%??^5]5K5TUN!)N+&B!H =W5X MSHY/3[Y>..R(FMPM.^Q8*3<"6;^ J1\C..8\\_O<^._OM^Q^[.J>;Z*YF:,K1 M.E(-[\!OLDD>C$F/W22BQ(X2QBQ.U806T/CR'0I[>1!U=9-B.1)L(#R*;(-, MQ0.1A-3%GKD=T;@@S22KQLKC8Y)^,]OFZ:9,Y]N2Z7P;"\U<#7W>G<[,A.G, MC+DW\2C]7T_C_)U-XU">2U=?4=2<#OQZ)1WYY4*1RG-<^A)C@TN7\)1__%1O M'%SW930=6#>"1?.G6?0@_'9XG)]044GXU)2*_EAKO9XQ$;$SG6*A 4^/\97Z MH2^[T6Q((8.2)FA%--D,IMJ27VH&W(W5N$X-_-";GD; M3SI79O^F2^ER0MCG'>V%^FG9),Z-"GTRB$^-94>7%^:>?3[25P\&.C'U3"A# MCY C:FGF]FF[0NJE9H+(?"N2VJWU=5PC91[KIN&1T#VER$BSD'ENW%<)V6\2 M$Q$ZWDBYW!TS/4*&Z0U=:G2/*">,- (JI"OU?8:A5"$UY3^";DGDXYNY*D69 M]$#^QSPZ!7N@"$DYT(:C--P?.\:6'4%_54E,W1.F*U-D?>K@!!>ZDLQ+7,B) M.@U<4VXS@X?I/Q,T_Q3T'7999F?D;63JB%Y4G>7+)%/LHA>.76 D^,E0]U[ MT^_(U;V4]#@6\O1;8CI(F4/+*%FU> MWW; !=D+./I+C97]E2W*OB MO*?7A;+%N,U./=2:=R<;+-/>%\XW//K%%\XW&!2LGV%X4:8T"19([S@%WWVZ M%\4C-!J$5E;A,+W\2A_YJ2:3##1+_;$7JMMQ'(Z',=TX$*Q&+"],)@&^B52&YG9TY]PLN8D?R&9!+DH23T_-FSCI M_L2[GDIW= _[6L^.0XIMR.[C@" ;$)QG(@C4;>FK%OHD_T&<4(:A2 4CUZB(083JA,)LU2%.28!J.IE&H##8W[_*2/7J6 M3POQP5C%H1KV*?+WB4)#O0XSI;2=P[.K7>(I(KG( MS!258FK-_1MDVYY'YF_#A&30S1;*I5'+P/43L]UZNMKCL.-QP$?\EET+MQ^8 M]?!,,K]R+?@JW>? ONNEJU0:)=W*B.*D/?=;01)Y2)K,YV^9R!;?>4B2'=]0 M1\=L3+_1I]U0#7* 5JKZ>=]XZ/8UO)5B2B[69S8JIB\Y3%,L?<6 >FO6-P_W M*,9/)VSVZ1DB-,KS2EA_XSZ-+,&N^D+$[ ^] **?<_^TEMU 8WQM.*HXC.?L M$YN[0\/E4=\Q_V;B[T2.2+'UXI'9TM)7.D@0H=[;H&=$!^D>'+/YYLZ9CX]5 M:E6+46-\G?WJ+]^]H-HJMZU*FW\RUVZ$,; VS/4T:(1) M<#1YYK80L)W+?_#!\.!XUVQ!H+0JX^Z/C7)U2L:SK<:A$(S8-NY'C^XT3C/! M4)B->!^K.W$V$D0H"X9+"7?0(CSWJ?@%T/O:S:G9<+A MW'K^2+"=K\;I#Q]0JZ&WQ+K9=**K AT?:=*=MNX!U= =)%T6FBPZNVS)7MTEV=8+ M>C5IUCU"?D7'BG6H!YQ4$$XZ%S'S541TPR/VL34;H XCA] C=D^/Z31'=Y:A MH-R$P.3>K=:B]ZX4RQVV/2=ZCT4BL8/-$FPLZ;/EBU:''97$[-&CYU8=,;+; MHJ\G\T.=8!=K^+ZG.@EK611XOGFZ7,/D_]6U-E)&&RR/4,Z1DMVV))AN5/@C M7Y;)9JM.)R6%*6@8QEU%P7=N5^QLLRUEHE[BQOHLBR<]<_S $Q'10AJ[=\2# MDW?IMJ"A<,T9ZJ_Z#K$@>G%5,O2%-]V@&[&=K]^/+J/=\KS%QHBZY5.H3S=- M?#%MQFL+MMS#>$5XSL!Y-?-L;A!8[E*Z$(/>ZJC9I!!P#E2H,U2NS_:G>\RT M0^DAKHNUF'67/*$19=ROD/C4^;+G#Z_FSZJ: V*!Z)%^RPZYC^ID^^3:,7-*YD?^X"!L>BPSOTPTRUW7K\9-X#SIZ]_2 GLQSN5'$SI@-I!LJLHA&8%K\ MPYDMAT+DOI3"D3)YFS MC&:;4*'@Q"C:<%QP),*8RR M+)1N,S/GID@KZ"F16:36[&0J.67%@$I^-NAR M7S*%?V0P4OY(1\%!8B:1B09#&?U(UUH2DB;SL-CHTBD]5!=#?I:OFC3YU'1_=F>LF< M1E:^KVX(FOVYVPOS.Q#R^P?FI"#I):86SIV3!O7JK>X_PIP:PEY.)AKK)4UAHGA8+&?FH84U/#5 2)#IBY=RSX M(+7I]$EE]KL)'F@XSFR5V_9)/>)R$*7Q@L[@W$E7]5^^ASI^$>R*LK,PK79V M)B?'X-FET&D^.W1-6%%MMYME_4MBBH*;,4&/GA0P'' =4'2[U&2] U3#1^&/ M.9PQ9Y"D_I)B0ETP!=TR7Z;\TO?2>$M'3TFN2"(EJH\\(AV6C_KM=(QW: AK M0@E4-LY-^NO<']:7ACORVV0>=F'R=37=RT?N(-'G/=-GEDY/QO@F_,T,HYR M[J6_I\EN.K92HVDH>$\OR$TJP>F'4?"8:Q+=3[G&8_4MIX\\R$@V!Y3^>CY6 M3=>Z!P,1ZM9F]>KN; 2>(?J0( Y>=IDQ:7;J-CTB-"VPPYEO*A2/I\G;@TUS M=#_7.)U9FLQ<,8,@];6T>)[6E.P>SH,^YOP]%+JDETYZIL*3I0'N8+S[D_9(E:B$VRP:?-'Y)PF_%E8KP)XJ:RI)L6KM)/2,DX/4>? MWE%W9)I9FCN+<-)]*;US/S9K*MFCJ/)=R(P#R. G!)/ M*P.$IA; 7V23+ZCACK\3X&= M32=.FCMFD;NF <9" _N-,=S/#'4_&%,$&05C4WC-*%/"431J)_0GR]Y1_J& M*+)Q07^:QB&:]61D-&HPK0F[Z1VD=J9]V+)@"3:6]-GZ:8!4! Y8CR*8,)B& M4X8T2IHT*);C8TW9;B;>L]# L%#V)HI0R$$G"2,QO<4PU.N2O;GD-Q4^PZ12 MJP6E6$;"[979M"DL_\?Q0Z.D>;;0Y#_XK\7JI0:-)"&DJ&)B?Y72.*+_6 M8/IB4EZ]DFU"61/(J(X_T1,=7:5%^>-G6N=D8F2"%YZ&1QTQB2KTS)*7QA$Z MP=>QF<]O,)O^QMUNM)N5W#^O0:'Z(A&P96I]]HY6_98=H@)+2PQL[@5/+T'Q MF^B1LYZ4V3\#?1>[:VE^Z826;V_Z0[_9@?@VK9!)1'II5%?G-_<;;\..LL$/ M8_7_[4\$(=WB5":A+\1N,IN#R;S?VV#KT\L7F-E>".T;?*UJN]QLU\KMSY^; MQ<%OVW.XS;U__"7(_?333W;"]AZ'"OJ,/J//Z#/ZC#ZCS^@S^HP^H\_H,_J, M/J//Z#/ZC#ZCS^@S^HP^H\_H,_J,/J//Z#/ZC#YO^U:%]&+=HGU]0$NZNIC! M]!CEM=Z^JU_)K,^ V@GN>QQ0.,]B"3:6]-EF@OGPZ]G%^=??+@XOC]GW/PXO MOQT>G?QY?7IT>';EL-/S(TL/!M@-Z='%^?')^=7),?OM\.SP_.B$7?UQG=EQ6!?T@Y+ST[.-][*V!X:RIV1-,R\=YDFL#CHJ M]$1HGJLK4E0.S.4EGX]5$N]WY:WP#M)7XU8K!JKL"^8$[S 2^Y$8SB^@J;XJ$>5RK5:XU?]8H?8J]1ZZIEIOM MQK/7M)K/7E,KMZKM9V]4J3Q_S48;1#^$]S'/QNR>&3X/P7YN1SU9.PU0]M,P M1?_A8"1"4\@U&]#I0)\7,CSF<9.1;(;VGIT>M[>(P\TUUQMB; ^F"T2%;X"H M+LXTY,$O'VH?,(+7(?@OL=F==VJLT1F*9JXB$L[<3EF"L@DUP$'@(&K3L7 S M"JJ"@C9$09L-/[/$9(I'LT*/9)'RIMV4J2>VNT>>>-72^J#M!;KW%BRY9+_>\HM&E);ZH7X%G MMX,5S;!%#,7!>^"]=\=[%;L=K&B&W53\GRU?O#0!J%4^.[5&A8"NF;'U$B,2 MBB^&?XLJL"RR,'9X=75W:?,5GK6(:5XY>;U->QH6U*,E4 8EK6L\ VDPQY8R MQROG^M> ^R*3_6\!/,!>#]AO%SR^+O9_IV'C8F5$CY(P3,LD1R*.]BW<^ % M6/%_#&#"O:8(Q#V73W&BAV#&_N[HYP\LN\K$HFN11 M/WN7&?V@WW4QXKZX^X9?S"]80%[;BZP]SO 1,Q#/JHL]UOK<=!JM!?=D;*\W M@:> ;-&0M8=3H !%4H!FTZE76_"F8N9_TQ&#S&\3SG/55V%<(L(9,&G>]S58 M/.W#!*$ELU7 %#. -I%,_;-3:>_! 0KM , 4F!8!4Q#UXD2=OH>[ 1DS<#D40B<@LJ:7ODW?O[-?"9(5=0K,$LF]_V!TV6)T-$!PL MSFXUYW-CP4. J[3MXF=MX6@PQC8; \ICD0V@/(LK3V/]JWM@.JL6!+-[+)W$ M5G-0V64>>[SM6L7[#0\HM < 4V!:!$S! MU,MMKFS5X !%RZ)0MVO%CG&IOUM2W5(2":SJ62D60-9"9"'&BW-.J[+^]3>+ MK+-EG@!D@6S1D 5[;VIS)=QATRG5Z])9)%.OVCBIA@3?V&R8U.5'AOH8&F8= M;%$,8&H)IM#?)1:=%MQ%@L%OR> 'IL"T")B"I'$"K2@N@!6GPB1)%^8@F:^" M7EJO XM.-BH&D+4062CR$L4[ZG"$K7$$( MDBX8LR!MK3L5R!ZPY%2"=.A9= M$8;"8UT9\,"508^Y*L)1)WLT8R%,<2JZ&.A#U0LU28KST,7P+YC!"C- 9*Q M'R*SN,CL?5[G?@D0FR7K=G>J;KQ1Z<@J:D<^:^JTZ@;6]&Q4J3>K(U0KUYJ: MUSR5='Q1K%#!'E=9_^MY7F%%A!S+E05I-Q9\4M./UU7P'GH MNM2,.&)#/N8=7V"VP1:VVD9,[1GW"ZY>OI/Y"'OLM->NPGU 2<"T2)C:0Q^@ M^6+0?-6I51R%B(+%5]&Q5M-%%K;'E\ LD"V:,B"OQ?G[_:B;Q> )VPZ M$\,RFA4YF#+EK9=+N#"A@5G6K<44\KPXR=3J6 LK]N@'IL"T")B"I9?8L=!H M8O07+7W"0I8%GC-)HEPUT/D3CZ4*S&)6*'P>TP=8R+)38X"LA9"%U_ M_1.+K+-EG@!D@6S1D 5[+[$-H;7@/!D\8=-Y&):Q-NHYE_J[)=4M)9'(UR!P MF)L5)ABJ4*=EF.&P16,6PA2O?B@&^H@"%N>R>FW!'&XU-D7Q2I@!9H"^6(4^ M] 7OK]MB_UK/^X4J;Y.>5G. V64D>WPN?;^0^[!('N9[[-(M(&LALE#[Q9FG MX51JF%7>'E\ LD"V:,B"OY>8#72J]07W9<(7-IU]8570TE7!0,1,=;$X:*O8 M %-+,(5T+W'L[3,.5!1[] -38%H$3,'2A5H.L\@X17/I:AGT1.!2HL5V(B'8N8H%:^]B$@.O<[%">S8M\0"[&&!;!"WX T,: M8-LM\C:Q92V'F%WT8T]P>25"/9EYJ"Z4Z52 M94,>LA'W$W' >!+W54B/H6OZ/*1;E%B@ F$F2IM.JT+-KE08C]F5&,9BT!$A MJU<<5JO4JN::8^%F?ZV:O])G=)>A<&,Y$O[X@,DHTH7']+4JB:.8?I!!;U5/ MX[U>*'H\UIMI_DZDEQ8Z2X$0@2M8NI92/Y@]]V.SM=Q3,>MCET( 60N1+9X" MVT/NRZW_PATL= <@"V2+ABPH?'$*;S:=SVTLQU/=*4KXUTLGE@C+L#4$DPAU=AM^\Y= )ABY6H+AC%@QLK55@?W MW^\N4CDO7:6JFK6B=.4F\++EG%4O4[W\_DCU[2)?(&LALL43-WMX$XM"6^<. M0!;(%@U94#@HO%CNL.)E(>2.ZW.@_U'Z(+=^J>E !:_,'^N5NPDDY9/-U>]V MK-:=6OVS?I*YIN[LD0"^2J*,%UAE\8 60N1A88O3D([M08\P5;CX(US MVT-20!;T;Q_#8%FLV*D?M?*UBKF?GGQ\](T,F&NR M2P*70!9A2)%L@&!DF;U.5:?5K-EGW<*%)-OL:C"&1<: ]EAD VC/,GMTG%8; MTK-->=**L^&YR\+5-\J#J\B#7Y@'^Y)WI"]C*2*'N2HP('=\D;UQ?OI6$U-D M9Q5),Q:5K9PQKI5K34^D5%KB79*R?>[?\'&43IB]2VS>KL^-=K.2^V'9U<..ST_*MOI<79#>G1Q?GQR M?G5RS*ZN#Z]/OIV<7U^QB]_9Q?>3R\/KTXOS*Z#Z>E1W_@QXXM&-O=TBP; M^I"UJ=RJ-9Z[IEJN5)Z[J%)NM_>>?5C]<^TM&D0/:SS7L[4V:$L0>F*-<&^Q M)<+U'+7>V\R,P3.,L[?\%!Q!2K7=?;?)F;RQ9H&T+OJ[D70R?U;OKYI;+5X_I OGE6Q)@#01H#0&> M4S_O\-^73OCK7 H$"VT%"R$R S$5@9B^BU JCW5#-6":D_Z;!PD/QZR>OEA. M_RDUZ\YIX!)?217LLKA/#>_U9Q^"R2Q@LLVFHF^__7\S 9HE?KDC W(SE40\ M\"*'B5OM?.GK(LWNU"'Y6OJ;QV/^^';4U9+N0N<-"N&IE@P#_,].WK.\T$C1# O> ^^!]PK >XCWP'O@/?#>>^,]Q'O%X;V5 MU8E;Z#"\A6P1@W!+9I)N121X*';-_NO M/#$2OAH."*DW.[RR6+/6>7[%(F>V>ZRLL\10\0(V>^S4<"KM.AS(EK@#F )3 M$#V(?@653)U6!40/4@*FA<+4'@(!T1>$Z.M.H]*"!X&5@&F1,+6'0<#TQ6#Z MFM-H+?@6IFUTH**L8SSQ9F"L9JS/>[Z*0(3<-XL9W!O(0$:QWB@Z$L5!\#FJ8O+4K M7:N8^TP]J&1B4\4@Z)85Z$.Q%G>SEE-O-FVR*K0*9H 9H#!6H0^%66;_0;-I M>9U'BXSY?IP+9K#"#% 8*]"'PBPQZ]9V*@TD,? NF,%*,T!BK$ ?$K-,S9A: MV_*7=%ADS"(OZ: X_8I=Z4Q%4?KNV6QQ1P4++NJ@!J>%&PV@,HN[QLX2JS'; MZPSVV.?Q5^Z^4],4F*> +!3 /H;966*U9'N=P1[[0 &VAZ> +!3 /H;9668U M8WN]P1X#00*VAZB +"3 /H;966*U87N=P1[[S%4 O/1E:^Q[JOE*1#&3@:L& MPF&!B->X]F>Y'VY:E!;"%'*TQ 9>U- O]N 'IL"T")B"I!2CB^*I97V#*./=MH/ M.KM<*:X-UA2>9]?"":P]UEPP/80A[\P)I8/20>F@=%"Z-ZT?!WZTS9K/5IM[WR^V M68.0$8AT_^"7#[4/*UM>+Q[?;3J" -C% -LB:,$?&-( NV!@6P0M^ -#&F 7 M#&R+H 5_8$@#;.RU?I?S6).]UFPHR$A]'@J'=7@D7<8#CWG23V+A635IB<4$ M+"9@,:%2KN]995:L)6#1?&MC=>A<$?P(.K>-.M=J6676PM&C/<:$SD'GH'/0 M.>C@<=&Z>SBU:&1WT:)LQ-[D'>ODUUZJ=:Z[5 M!\ ?T=TZH<2. AL7N6T=W0 ;.Y*P(^F=#VF #?X ?V!( ^P"@&T1M. /#&F M78@=T7D0LWLLM$DZ PLO4GVAD?]MOBR\$B=@>4^D>Z94'-!I0&+@8[ MV&H'*(T=\$-IEDAJZDZSONTZEAG>J M6>QBA=E2NY6+=FM;FK8(9AME!,@"60N1!3-@_ )9((OM;-8$:P!["\"V"%KP M!X8TP"[$=E@4"'[K&<(C-:"[]440R9$PI8+WEV>LA>8-X3YKF9X%S&N!V2)0 M;8]O,(SM'<: &6P!ML P!LP6P6P1J& +#&/ ;-M\R9:^==J>69/):Y4P;6ZK MA18L+OJNIG_ML=9.RZDW%MRD"&^RMN3U]IIFTP'7]B)KSZ"'A!1*0FI.L[G@ MX5UX$R0$$K(UR-HSZ"$AA9*0:MNIU!IP)UL-! V!AKR[00\-*92&-)Q:>\%7 MO<&;+'BI#7:J6FJY5*?2?_\9$*8^?=4SRS!,!2SJJS N$5D-F Q&(HH'A&+D ML$#$&SO\7BDW*]0Q%BE?>J@J81'ZD+@EZA=MKD3>').BF 3, #- 7JQ"'_*R M3)QW6ZM4&U89%NP&,\ ,$!FKT(?(++-;8,%E'A";999<<$T(=GP/% GT(5#% M%"AD0=;[%\[K%"9(>%CE9.TKM-M3<-P>LZY_:P3JEJ_M/%!]_>>!MK!TN3TV M7?_FO2TTYZ8S!@B@53X% =Q6 =S,::8M9$Q[; H!A !" "& =MC5=@'49[$: M"[XA$91IIU&A@%! *" 4T Z[VJZ FSE)MH6,:8]-GSQ]1O_E!++Y\3$X?UXO MFC.G7;D"H=<;[O7:8@WT&7W>YC[WI[M!AKPG4MTM\2Y1RC[W;_@X,OM"OGSJ M*&_\ZW]]^=2/!_ZO_Q]02P$"% ,4 " !V@F13.Y%ZZ1D4 !3W@ $0 M @ $ ;&)P:"TR,#(Q,3$P-"YH=&U02P$"% ,4 " !V M@F13JCA4V$T# "#"P $0 @ %(% ;&)P:"TR,#(Q,3$P M-"YX&UL4$L! A0#% @ =H)D4ZSB M'Q_?!P U%4 !4 ( !P!T &QB<&@M,C R,3$Q,#1?;&%B M+GAM;%!+ 0(4 Q0 ( ':"9%.1$ 3%> 4 /,X 5 " M =(E !L8G!H+3(P,C$Q,3 T7W!R92YX;6Q02P$"% ,4 " !V@F13J^^@ M^>,G >-00 #P @ %]*P ;&)P:"UE>#DY7S$N:'1M4$L% 3!@ & 8 A $ (U3 $! end